5 years later, CAR-T pioneer Kymriah offers jaw-dropping evidence of durable remissions — even as it still proves a tough sell
Just a couple of weeks after Bristol Myers Squibb finally won an FDA OK for liso-cel, investigators at Penn posted a 5-year update on a small group of patients suffering from non-Hodgkin lymphoma who were treated with Novartis’ pioneering CAR-T Kymriah. And it’s impressive.
For these advanced, treatment-resistant NHL patients, 46% had achieved a complete remission, with 31% marking progression free survival at the 5-year point. And researchers determined that durable success here hinges on patients’ response one year into the treatment. This is the longest stretch yet reported on for these patients.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.